fda drug shortages tirzepatide zepbound shortage status 2025 confirms is still over, gives compounders a grace period FDA approval for Zepbound (tirzepatide)

& Naito, S

Do not rub the injection site, as this can accelerate medication dispersion and cause local irritation

All products are recommended to be dosed once daily with total daily doses between 157.8 mg and 1200 mg, with a median and mode of 400 mg (mean 472.2 mg)

Clinical Considerations Disease-Associated Maternal And/Or Embryo/Fetal Risk Appropriate weight gain based on pre-pregnancy weight is currently recommended for all pregnant patients, including those with obesity or overweight, due to the obligatory weight gain that occurs in maternal tissues during pregnancy

The applicability to women on GLP-1 therapy specifically is not yet studied

Semaglutide Blood Tests & Monitoring Semaglutide is an approved GLP-1 receptor agonist used in diabetes and weight-management contexts